home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  
 

registry of biomedical companies

 
  November 16, 2018
promoting the transfer of scientific know-how between industry and academia
 
 
Registry of biomedical companies:

[1] [3] [4] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Z] 549 active entries

Replicor Inc.

6100, avenue Royalmount
Montreal, QC, H4P 2R2
Canada

Phone: 450-688-6068
Fax: 514-496-9021

Description:

Replicor is developing a new drug that will revolutionize the

treatment of patients with chronic hepatitis B which

affects up to 350 million patients worldwide. By blocking the release of a

viral protein called HBsAg, our drug allows the re-establishment of a

proper immune response to the infection and results in a high proportion of

patients achieving long term immunological control over their infection.

 

The efficacy and safety of our drug has already been successfully

demonstrated in a randomized phase II human clinical trial. Based on

Replicor's current clinical trial results, it is projected that a functional

control rate of 80% will be achieved when our drug is used in combination

with currently available approved drugs. The most effective treatment to

date can only achieve a rate of functional control less than 10 %.

 

Co-infection with hepatitis B and hepatitis D affects 15-20 million patients

worldwide and is the most aggressive form of viral hepatitis leading to a

high rate of cirrhosis. No drug has been approved for this condition making 

this an orphan drug indication with the possibility of accelerated approval

by the FDA and EMA. We have demonstrated in a recent proof of concept

clinical trial published in The Lancet Gastroenterology & Hepatology, that

7 patients out of 11 have completely eliminated the HDV virus from their

blood when receiving our drug in combination with Pegasys making our

drug the most promising asset in this field.

Longer treatment durations are expected to achieve higher rates of cure for this condition.

 

 

 

 

 

 

 



Selected Categories:
Product Company   Service Company
Biopharma
- Research
Biotech
- Research
Pharmaceutical
- Research

Last update of this entry: June 05, 2018

   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2018 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.